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A B S T R A C T
Background
Otitis media (inflammation of the middle ear, usually caused by infection) affects people of all ages, but is particularly common in
young children. Around 164 million people worldwide have long-term hearing loss caused by this condition, 90% of them in low-
income countries. Because zinc supplements prevent pneumonia in disadvantaged children, we wondered whether they prevent otitis
media.
Objectives
To evaluate whether zinc supplements prevent otitis media in adults and children of different ages.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 2) which includes
the Acute Respiratory Infection Groups’ Specialised Register; MEDLINE (1950 to June Week 1 2009); and EMBASE (1974 to June
2009).
Selection criteria
Randomised, placebo-controlled trials of zinc supplements given at least once a week for at least a month for preventing otitis media.
Data collection and analysis
Two review authors assessed the eligibility and methodological quality of the included trials, extracted and analysed data and wrote
the review. We summarised results using risk ratios or rate ratios for dichotomous data and mean differences for continuous data. We
combined trial results where appropriate.
Main results
We identified 12 trials for inclusion, 10 of which contributed outcomes data. In trials of healthy children living in low-income
communities, two trials did not demonstrate a significant difference between the zinc supplemented and placebo groups in the numbers
of participants experiencing an episode of definite otitis media during follow up (3191 participants), while another trial showed a
significantly lower incidence rate of otitis media in the zinc group (rate ratio 0.69, 95% confidence interval (CI) 0.61 to 0.79, n =
1621). A small trial of 39 infants undergoing treatment for severe malnutrition suggested a benefit of zinc on the mean number of
episodes of otitis media (mean difference -1.12 episodes, 95% CI -2.21 to -0.03). Zinc supplements did not seem to cause any serious
adverse events, but a small minority of children were reported to have vomited shortly after ingestion of the supplements.
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Authors’ conclusions
Evidence on whether zinc supplementation can reduce the incidence of otitis media in healthy children under the age of five years
living in low- and middle-income countries is mixed. There is some evidence of benefit in children being treated for marasmus, but
this is based on one small trial and should therefore be treated with caution.
P L A I N L A N G U A G E S U M M A R Y
Zinc supplements for preventing middle ear infections
Middle ear infections are common, especially among young children, usually causing earache and some temporary (occasionally
permanent) hearing loss. Zinc is an essential micronutrient, which has a role in the optimal functioning of the immune system and
resistance to infection. Some people, especially children in low- and middle-income countries, may not have adequate zinc intake
from food alone. Researchers have therefore examined the potential role of zinc supplements in preventing infective illnesses, including
middle ear infections.
The review authors searched the medical literature for studies which compared middle ear infections in people randomly selected to
receive zinc supplements or not receive supplements. Ten eligible studies were found, all conducted among young children. The results
of the studies provided no convincing evidence that zinc supplements reduce the occurrence of middle ear infections in healthy children.
However, in one small study of severely malnourished children, those receiving zinc supplements had fewer middle ear infections.
B A C K G R O U N D
Description of the condition
Acute otitis media (inflammation of the middle ear, usually caused
by infection) affects people of all ages throughout the world, par-
ticularly young children under the age of three years, in whom it
is very common. It causes acute pain for a day or so, and tem-
porary conductive deafness for longer. Usually it resolves quickly
but it can lead to chronic conditions. The greatest burden is from
chronic suppurative otitis media (discharge through a perforation
in the ear drum), which affects between 65 to 328 million people
worldwide; around 164 million people have hearing loss caused
by this condition, 90% of them in low-income countries (WHO
2004).Other complications of otitismedia includemeningitis and
brain abscess, causing about 28,000 deaths worldwide, mostly in
low-income countries (WHO 2004).
Description of the intervention
Zinc is an essential micronutrient important for immune function
and resistance to infection. It must be consumed regularly as it
cannot be stored in the body. Mild to moderate zinc deficiency
impairs immune function but has no obvious symptoms (Walker
2004). Zinc is found in a variety of foods, including most animal
proteins, and some nuts, beans, and seeds. Absorption of zinc is
inhibited by phytates, found in many cereals and legumes. Diar-
rhoea causes zinc loss from the body. Over 60% of children under
the age of five have zinc deficiency from inadequate diets in some
low-income countries (Caulfield 2004).
Zinc supplements are recommended by the World Health Orga-
nization (WHO)/United Nations International Children’s Fund
(UNICEF) as an adjunct in the treatment of diarrhoea (WHO/
UNICEF 2004), based on an analysis of effectiveness and costs
(Robberstad 2004). There have also been a number of successful
trials using zinc supplements in the prevention and treatment of
pneumonia and other respiratory infections (Bhutta 2004). A sys-
tematic reviewpublished in 1999 concluded that zinc supplements
prevent pneumonia in economically disadvantaged children living
in low- and middle-income countries (ZICG 1999).
How the intervention might work
Children who experience recurrent otitis media have lower zinc
levels than healthy controls (Bondestam 1985). Zinc supplemen-
tation helps prevent and cure respiratory and diarrhoeal diseases,
and so it might have a similar effect against otitis media.
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Why it is important to do this review
There are currently no published reviews on zinc supplements for
the prevention of otitis media, or hearing loss and other compli-
cations arising from otitis media. Although a preliminary search
revealed no published zinc supplementation trials with otitis me-
dia as a primary outcome, some trials which assess zinc for the
prevention of other acute respiratory infections also record otitis
media as an outcome.
O B J E C T I V E S
To evaluate whether zinc supplements prevent otitis media in
adults and children of different ages.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
People of all ages, male or female.
Types of interventions
Zinc salt supplements, at any dose, given at least once a week, for at
least one month versus placebo. Trials giving other micronutrients
in addition to zinc were included if the only difference between
the two groups was zinc.
Types of outcome measures
Primary outcomes
1. Number of participants with at least one episode of definite
acute otitis media during follow up, diagnosed by clinical
assessment of the ear.
2. Number of episodes of definite acute otitis media per
participant per year of follow up.
3. Number of days with definite otitis media (acute or
chronic) per participant per year of follow up.
Secondary outcomes
1. Number of participants with at least one episode of
probable acute otitis media during follow up, indicated by ear
pain, ear discharge or other indicator as specified by the trial
author.
2. Number of episodes of probable acute otitis media per
participant per year of follow up.
3. Number of days with probable otitis media (acute or
chronic) per participant per year of follow up.
4. Adverse events: any adverse events as reported by the trial
authors.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (The Cochrane Library 2009, issue 2), which in-
cludes the Acute Respiratory Infection Groups’ Specialised Reg-
ister; MEDLINE (1950 to June Week 1 2009); and EMBASE
(1974 to June 2009).
The following search terms were used to search MEDLINE and
CENTRAL. We combined the MEDLINE search string with the
Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision); Ovid format (Lefebvre 2008). The
search string was modified for EMBASE (see Appendix 1).
MEDLINE (Ovid)
1. exp Zinc/
2. zinc.tw.
3. exp Dietary Supplements/
4. 1 or 2 or 3
Searching other resources
We attempted to contact trial authors and other researchers in the
field to identify additional studies that may be eligible for inclu-
sion. We also contacted the WHO for unpublished and ongo-
ing trials. There were no language or publication restrictions. We
handsearched the references of all identified studies.
The search strategy was designed to identify all trials using zinc
supplementation as an intervention, as we were aware that otitis
media was likely to be only a secondary outcome in the majority
of trials recording this outcome.
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Data collection and analysis
Selection of studies
One review author (KA) screened the citations identified by the
search strategy to exclude those which obviously did not refer
to a study assessing zinc supplementation for the prevention of
illness. Where there was any doubt we did not exclude citations at
this stage. Two review authors (KA, AG) independently screened
the abstracts of the remaining citations; obtaining copies of the
full text reports where abstracts were not available. Full reports of
potentially eligible studies were obtained and assessed for inclusion
in the review by the same two review authors using a pre-designed
eligibility form based on the inclusion criteria. We contacted trial
authors for clarification in the event that it was unclear whether
a trial was eligible for the review. We resolved any differences in
opinion by discussion. We excluded studies that did not meet the
criteria and, with the exception of those excluded on the basis of
the citation alone, documented the reasons for exclusion.
Data extraction and management
Two review authors (KA, AG) independently extracted data using
a tailored data extraction form. We extracted data on study de-
sign, participant characteristics, interventions, and outcomes. For
dichotomous data, we extracted the number of participants with
the outcome, the total number randomised to each group, and the
total number analysed. For continuous data, we planned to extract
the arithmetic mean for each group and their standard deviations.
If medians had been used, we planned also to extract ranges. We
planned to extract geometric means if presented by the trial author
because of skewed data. We resolved any discrepancies between
the extracted data by discussion and, if required, by referral to a
third review author (HS). If data were unclear or not presented
in the paper, we attempted to contact the trial authors for further
details.
Assessment of risk of bias in included studies
Two review authors (KA, AG) independently assessed the risk of
bias of the included trials using a pro forma. We contacted trial
authors if details were missing in the publications or if they were
unclear. In case of disagreement, we planned to consult a third
person. We categorised the generation of the allocation sequence
and allocation concealment as adequate, unclear, or inadequate
as in Juni 2001. We assessed whether, for the primary outcome
of otitis media, the participants, care providers and investigators
were blinded to which participants received zinc supplements as
described in Higgins 2008. For otitis media outcomes, we assessed
that incomplete outcomes data had been adequately addressed if
85% or more of the participants were included in the analysis, or
if less than 85% were included but adequate steps were taken to
ensure or demonstrate that this did not bias the results. We also
examined the trial reports for any evidence of selective reporting of
outcomes or any other issues that may bias the results.We reported
the results of the assessment in a table.
Measures of treatment effect
We analysed the data using Review Manager 5 (RevMan 2008).
For dichotomous data, we calculated the risk ratio or rate ratio
and if appropriate we combined results from different trials. We
calculated mean differences for continuous data. All results were
presented with 95% confidence interval (CI). Data presented by
the trial authors in other formats were described in the text.
Assessment of heterogeneity
We planned to assess heterogeneity between the trials by exam-
ining the forest plot to check for overlapping CIs, using the Chi
2 test for heterogeneity with a 10% level of significance, and the
I2 statistic using a value of 50% to represent moderate levels of
heterogeneity. If heterogeneity was detected and it remained clini-
cally meaningful to combine the trials, we planned to use the ran-
dom-effects model.We planned to explore heterogeneity using the
following subgroups: type of supplement; length of supplemen-
tation; and participant age (adults, children, children of different
ages). However, there were insufficient trials with similar outcome
measures to undertake these analyses.
Assessment of reporting biases
We planned to assess the likelihood of small study effects, such
as publication bias, by examining the funnel plot for asymmetry.
However, there were insufficient trials reporting on the same out-
comes to do this.
Sensitivity analysis
Providing there were sufficient trials, we planned also to conduct
a sensitivity analysis to investigate the robustness of the results
taking into account the quality components. However, there were
insufficient trials to do this analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
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Results of the search
The search identified 5678 records. After an initial scan of the
titles, we identified 144 citations that could not be excluded from
the review on the basis of title alone. From this list, we identified 12
trials that met the inclusion criteria. The excluded studies, and the
reasons for their exclusion, are documented in the Characteristics
of excluded studies table. Of the 12 included trials, two had ex-
tremely small sample sizes (21 and 49 participants respectively)
and did not have any reported cases of otitis media in their partic-
ipants, either in the intervention or control groups (Prasad 1999;
Prasad 2007). These two trials are presented in the Characteristics
of included studies table, but as they have no relevant outcome,
they do not contribute to the conclusions. A further three trials
may have met the inclusion criteria, but we were unable to con-
tact the trial authors for clarification; these trials are listed in the
Studies awaiting classification reference section.
Included studies
Location
Nine trials were conducted in low- and middle-income coun-
tries, includingBangladesh (Brooks 2005), India (Bhandari 2002),
South Africa (Bobat 2005), Burkina Faso (Muller 2001), Chile
(Schlesinger 1992), Peru (Penny 2004), Ecuador (Wuehler 2008),
Jamaica (Gardner 2005), and Indonesia (Lind 2004); and one trial
was conducted in the USA (Heinig 2006). Two further trials were
conducted in the USA; these are excluded from the analysis be-
cause no cases of otitis media were identified (Prasad 1999; Prasad
2007).
Participants
All the trial participants included in the analysis were children
aged under five years at the start of the trials. All but one (Bobat
2005) included only children under the age of three years. All trials
included both males and females.One trial included only children
who had HIV infection and were not receiving antiretroviral ther-
apy (Bobat 2005), and one included only infants with marasmus
(Schlesinger 1992), one enrolled only children with persistent di-
arrhoea (Penny 2004), while others included only healthy children
or children from the general population. The two trials excluded
from the analysis involved adults with sickle cell disease (Prasad
1999) and elderly adults attending a senior citizens’ centre (Prasad
2007). The trials varied widely in size; one trial had fewer than
50 participants (Schlesinger 1992), two had more than 50 but less
than 100 participants (Bobat 2005; Heinig 2006), two had more
than 100 but less than 250 (Gardner 2005; Penny 2004), three
had around 600 to 700 participants (Lind 2004; Muller 2001;
Wuehler 2008), and the two largest trials had 1621 (Brooks 2005)
and 2482 (Bhandari 2002) participants respectively.
Interventions
Zinc supplements were provided in the form of zinc sulphate (
Bobat 2005; Gardner 2005; Heinig 2006; Lind 2004; Muller
2001; Wuehler 2008), zinc gluconate (Bhandari 2002; Penny
2004; Prasad 2007), zinc acetate (Prasad 1999; Brooks 2005),
and zinc chloride (Schlesinger 1992). Supplements were given for
periods of 105days (duringnutritional rehabilitation) (Schlesinger
1992), four months (Bhandari 2002), six months (Bobat 2005;
Gardner 2005; Heinig 2006; Lind 2004; Muller 2001; Penny
2004; Wuehler 2008), and 12 months (Brooks 2005). Zinc or
placebo was given daily (or six days a week) in all trials, except one
which gave supplements weekly (Brooks 2005).
Outcomes
Primary
Two trials reported on the number of children having at least one
episode of otitis media during follow up, diagnosed by clinical
assessment of the ear (Bhandari 2002; Muller 2001); one trial also
reported on the number of children with more than one episode
during follow up (Bhandari 2002).
Three trials reported on the number of episodes of diagnosed otitis
media with ear suppuration per participant per year of follow up
(Brooks 2005; Heinig 2006; Schlesinger 1992), although one trial
(Heinig 2006) presented these data only in graph form, and the
exact numbers could not be extracted.
No trials reported on the number of days with definite otitismedia.
Two trials in adults reported individual infections, and described
the type of infections. None of the infections reported in these
trials were otitis media (Prasad 1999; Prasad 2007).
Secondary
Two trials reported on the number of participants with at least one
episode of probable otitis media, defined as ear discharge reported
by the mother (Bhandari 2002; Gardner 2005), although one trial
did not present any numerical data for this comparison (Gardner
2005).
One trial reported on the mean number of days with reported ear
discharge (Bhandari 2002). Another reported on the total number
of days with ear discharge for the entire population within each
group (Lind 2004); these data are not presented in meta-analysis
because of the potential that it may be skewed by a small number
of children with chronic otitis media. Another recorded mean
proportion of days with earache or ear discharge, and presented
the conclusion but not the actual data (Wuehler 2008).
Adverse events
Three trials reported on vomiting following supplementation (
Bhandari 2002; Lind 2004; Penny 2004), andone trial reported on
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withdrawals from the study due to regurgitation of the supplement
syrup (Bobat 2005).
Other
One trial, involving only childrenwithHIV infection attending an
HIV clinic but not receiving antiretroviral treatment, reported on
the number of clinic attendances, and the number of attendances
where otitis media was diagnosed.
Risk of bias in included studies
This section reports only on the included trials that contributed
to data in the analysis.
Allocation
Seven of the trials included in the analysis reported an adequate
method of random sequence generation and of concealment of the
allocation sequence. One trial reported adequate sequence genera-
tion but did not describe allocation concealment (Wuehler 2008).
In the remaining two trial reports the methods of sequence gener-
ation and allocation sequences were not described (Gardner 2005;
Schlesinger 1992).
Blinding
Seven of the trials included in the analysis reported that knowledge
of the allocated interventions was adequately concealed during the
trial (blinding of all relevant individuals involved in the trial); the
remaining three trials (Gardner 2005; Schlesinger 1992; Wuehler
2008) did not provide details of blinding, although Schlesinger
1992 andWuehler 2008 were stated to be ’double-blind’ and ’dou-
ble-masked’, respectively.
Incomplete outcome data
All ten of the trials included in the analysis had either almost com-
plete outcome data, or had adequately addressed any incomplete
outcome data.
Selective reporting
None of the trials included in the analysis showed any evidence
of selective reporting, although this was difficult to assess because
the outcomes of interest were not the primary outcomes of any of
the trials.
Other potential sources of bias
There was no clear evidence of any other bias in any of the trials
included in the analysis, although one trial (Heinig 2006) did not
give clear information on how the trial sample was selected, and
another (Schlesinger 1992) did not provide sufficient method-
ological details to judge the risk of other bias.
Effects of interventions
Definite otitis media
In two trials conducted in community settings (Bhandari 2002;
Muller 2001), there was no significant difference between zinc or
placebo in the number of children with at least one episode of
definite otitis media during follow up (3191 participants, two tri-
als, Analysis 1.1). There was also no significant difference between
zinc and placebo groups in the numbers experiencing more than
one definite episode (2482 participants, one trial, Analysis 1.2).
One community trial (Brooks 2005) reported a lower incidence
rate of diagnosed otitis media with zinc supplements compared
with placebo (rate ratio 0.69, 95% CI 0.61 to 0.79, Analysis
1.4). This trial included a younger age group than the two trials
described above (60 days to six months, compared with six to 36
months and six to 31 months).
In a small trial involving infants with marasmus (Schlesinger
1992), there was a significant benefit of zinc on mean number of
episodes of otitis media (mean difference -1.12 episodes, 95% CI
-2.21 to -0.03, 39 participants, Analysis 1.3). Another trial, in-
volving breast fed infants in the USA, presented data on episodes
of diagnosed otitis media per 100 days at risk, in graph form only
(Heinig 2006); although it was not possible to extract numerical
data, it was apparent from the graph that there was no significant
difference between the zinc and placebo groups, the rate in each
group being approximately 0.6 episodes per 100 days at risk.
In a trial involving 96 children with HIV infection and not re-
ceiving antiretroviral therapy (Bobat 2005), ear infection was di-
agnosed in 39 of 360 (10.8%) scheduled clinic visits and 46 of
407 (11.3%) total visits of children in the zinc group; while in the
placebo group, ear infection was diagnosed in 52 of 370 (14.1%)
scheduled visits and 65 of 447 (14.5%) total visits. The trial au-
thors reported that this represented no significant differences be-
tween the groups.
Probable otitis media
In a trial within a community setting (Bhandari 2002), there was
no significant difference between the zinc and placebo groups in
the number of children who had at least one episode of probable
otitis media of any duration (2482 participants, one trial, Analysis
1.5). This trial also reported no significant difference between the
zinc and placebo groups in mean days with ear discharge (3145
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participants, Analysis 1.6). In another community trial (Gardner
2005), there was no difference between the zinc supplemented and
placebo groups in the median number of episodes of diagnosed
ear infection (0.2 (range 0 to 5) compared with 0.0 (range 0 to 2)),
or median time with ear infection (0.0 (range 0 to 28) compared
with 0.0 (range 0 to 15)).
In one community trial including infants from birth to 12 months
(Lind 2004), the zinc supplemented group spent a total of 21 of
30,275 days of follow up with ear discharge, compared with 37 of
30,423 days in the placebo group (risk ratio 0.57, 95% CI 0.33
to 0.97, 340 participants, Analysis 1.7). This appears to represent
a significant risk reduction in the zinc supplemented group in the
number of days spent with ear discharge; however it is unclear
from these data howmany children were affected by ear discharge,
and whether the data were skewed by one or two individuals who
may have developed chronic ear discharge.
A further community trial reported that the overall proportion
of days spent with earache or ear discharge was less than 1% in
the zinc and placebo groups, and that there was no significant
difference between the groups (Wuehler 2008).
Adverse events
One trial reported no difference between zinc and placebo in the
proportion of doses givenwhere vomiting followedwithin 15min-
utes (0.6% in each group, 246 participants, Penny 2004), while
another (Bhandari 2002) reported more days of vomiting with
zinc than placebo (mean difference 1.70 days, 95% CI 1.31 to
2.09, 2842 participants, one trial, Analysis 1.8).
One trial (Lind 2004) reported no significant difference between
the zinc and placebo groups in the number of children who vom-
ited after ingesting the supplement (100 participants, Analysis
1.9). One (Bhandari 2002) reported that 8 of 1421 children in
the zinc group discontinued supplementation because of vomit-
ing, compared with 0 of 1421 in the placebo group; however, this
difference was not significant (Analysis 1.10).
One trial reported that 9.1% of the participants dropped out be-
fore the end of the study (Bobat 2005). The most common reason
in both the zinc and placebo groups was a reaction to the taste of
the syrup resulting in regurgitation; this was most common in the
youngest participants.
No trials reported any serious adverse events.
D I S C U S S I O N
Summary of main results
Six of the included trials showed no evidence of a difference be-
tween zinc supplements and placebo on otitis media incidence or
prevalence in children.These included a small trial of childrenwith
HIV/AIDS, another small trial of breast fed infants in the USA,
and three larger trials conducted within poor communities in low-
or middle-income countries. One trial conducted within a com-
munity setting showed a possible benefit of zinc in infants from
birth to 12 months, but the findings were difficult to interpret.
However, two trials appeared to demonstrate a definite significant
benefit of zinc supplementation; one of these trials involved only
infants with marasmus, the other involved healthy infants aged
60 days to 12 months living in a poor urban community. While
the two trials including only infants under the age of 12 months
appeared to show a beneficial effect of zinc, and other trials in-
cluding also the older age groups showed no beneficial effect, it is
not possible to assess whether this effect is due to age differences
as analyses stratified by age were not available for the other studies
included in the review.
Overall completeness and applicability of
evidence
All of the trials included in the analysis involved only young chil-
dren under the age of five years, and most included only children
under the age of three years, the age group in which otitis media
is most common. Nine of the 10 trials were conducted in low-
andmiddle-income countries, where zinc deficiency among young
children is common, and supplements most likely to be beneficial.
Therefore these trials were applicable to real life situations where
the use of supplements to prevent otitis media and other adverse
health outcomesmay be considered. In all the included trials, otitis
media was a secondary outcome; the primary outcomes usually be-
ing more serious illnesses such as pneumonia, malaria, diarrhoea,
lower respiratory tract infection, or death. However, as data on
otitis media were collected using the same methods as the primary
outcomes, this should not have adversely affected the quality of
the data collected. The main weakness of the data is that most
trials, when presenting data, did not differentiate between acute
otitis media and chronic suppurative otitis media, which may have
more severe consequences including permanent deafness.
Quality of the evidence
The trial evidence included is generally of good quality, with a low
risk of bias. Seven of the nine trials included in the analysis re-
ported adequate allocation concealment, seven reported blinding
the participants and trial staff, and all ten reported a low rate of
loss to follow up. The majority were carefully conducted commu-
nity trials, with active mechanisms to promote adherence to the
intervention, and active case finding.
Potential biases in the review process
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All the included trials, as expected, included otitis media only as
a secondary outcome. There was therefore the potential to miss
trials which were less publicised or less well indexed within the
electronic databases. We tried to avoid this by conducting a wide
search and assessing the relevance of each paper identified in that
search carefully. However, only one author was able to find the
time to assess all 5678 titles identified in the search, so there is a
small possibility that relevant trials may have been inappropriately
excluded at this stage. There are no other obvious sources of po-
tential bias.
Agreements and disagreements with other
studies or reviews
We are unaware of any similar reviews covering this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence on whether zinc supplementation can reduce the inci-
dence of otitis media in healthy children under the age of five years
living in low- and middle-income countries is mixed. Three out of
the five trials assessing this outcome demonstrated no significant
effect, with point estimates close to no effect; another trial sug-
gested a possible benefit of zinc, but the findings were difficult to
interpret, and another trial appeared to demonstrate a significant
benefit. The trial demonstrating a benefit of zinc included only
children aged 60 days to 12 months. There were no trials in adults
or older children, but both otitis media and zinc deficiency are
much less common in these groups.
There is no clear evidence onwhether zinc supplements can reduce
otitis media specifically in children with HIV/AIDS, as only one
small study was conducted among this group, and involved only
children not receiving antiretroviral treatment.
There is some evidence that zinc supplements may reduce otitis
media in infants being treated for marasmus. However, this con-
clusion is based only on one small trial, so must be viewed with
caution.
Implications for research
Although initial results do not seem promising, it is still unclear
whether zinc supplements can prevent otitis media in poor com-
munity settings, and if so, which particular types of communities
may benefit, and which age groups.
Future trials assessing zinc supplements for the prevention of mor-
bidity in childhood could incorporate otitis media as an outcome.
Such trials should take care to collect and code data on otitis media
outcomes accurately, including differentiating between different
forms of otitis media, and to analyse and present the data in man-
ner that is appropriate and suitable for combining with other trial
data in meta-analyses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bhandari 2002
Methods Randomised controlled trial (simple randomisation in blocks of 8)
Duration: February 1998 to September 2000
Participants Number: 2482 enrolled
Inclusion criteria: aged 6 to 30 months, male and female
Exclusion criteria: consent refused, likely to move out of the study area within the next 4
months, needed urgent admission to hospital on the enrolment day, received a massive
dose of vitamin A within last 2 months
Interventions Group1: zinc gluconate syrup taken daily for 4 months (contained 10 mg elemental zinc
for infants and 20 mg for older children)
Group 2: placebo syrup
Outcomes Included in the review
In passive surveillance at clinics: acute suppurative otitis media defined as pus draining
from ear for less than 2 weeks duration plus otoscopic examination reveals redness,
decreased mobility and/or bulging of ear drum. Two episodes of otitis media separated
by ≥ 6 weeks
Chronic suppurative otitis media defined as pus discharge from ear for more than 2
weeks and/or recurrent ear discharge
In active surveillance: reported discharge from the ear, obtained during weekly surveil-
lance visit by field workers
Measures include children with at least 1 episode of clinically diagnosed otitis media
during follow up, children with at least 1 episode of reported ear discharge during follow
up, and mean number of days with reported ear discharge at follow up
Not included in the review
Acute lower respiratory infections
Pneumonia
Diarrhoea
Notes Location: India
Setting: community setting (urban slum)
Source of funding: Indian Council for Medical Research
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “The randomisation scheme was
generated by a statistician at Statens Serum
Institute using SAS software”
Comment: done
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Bhandari 2002 (Continued)
Allocation concealment? Yes Quote: “The randomisation scheme was
generated by a person not otherwise in-
volved with this study”
Comment: done
Blinding?
All outcomes
Yes Quote: “The zinc and placebo syrups were
similar in appearance, taste and packaging.
Maskingwasmaintained during analysis by
coding the groups A and B”
Comment: done
Incomplete outcome data addressed?
Otitis media
Yes 2226 of 2482 (89%) participants followed
up for 4 months, a similar percentage in
the placebo (91%) and zinc (88%) groups.
Only 8 children (all in the zinc group) dis-
continued the trial because of vomiting
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
Bobat 2005
Methods Randomised controlled trial. Randomised in blocks of 8 in 3 age strata
Duration: March 2003 to September 2004
Participants Number: 96 enrolled
Inclusion criteria: HIV-1 infection, aged 6 to 60 months (age strata 6 to 23, 24 to 42,
and 42 to 60 months), male or female, hospital outpatients, not receiving antiretroviral
therapy. Children receiving a single dose of nevirapine to prevent transmission were
included
Exclusion criteria: none stated
Interventions Group 1: zinc sulphate tablets (10 mg elemental zinc) daily for 6 months
Group 2: placebo
Outcomes Included in the review
Presence of otitis media diagnosed by history and examination, including otoscopy, at
routine and additional visits to the HIV clinic
Not included in the review
Watery diarrhoea
Pneumonia
Upper respiratory tract infection
HIV-1 viral load and CD4 + T lymphocyte %
Notes Location: South Africa
Setting: hospital outpatients
Source of funding: Johns Hopkins Family Health and Child Survival Cooperative Agree-
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Bobat 2005 (Continued)
ment with the Office of Health, Infectious Diseases and Nutrition, Global Health Bu-
reau, US Agency for International Development
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomisation lists were com-
puter generated”
Comment: done
Allocation concealment? Yes Quote: “Randomisation lists were gener-
ated at the WHO”
Comment: done
Blinding?
All outcomes
Yes Quote: “The investigators were unaware
of the treatment allocation until follow-up
was completed”
Comment: done
Incomplete outcome data addressed?
Otitis media
Yes 85 of 96 children (89%) completed the
protocol. Of the 11 that did not complete
the study, 2 dropped out and 9 died
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
Brooks 2005
Methods Randomised controlled trial. Random assignment with permuted blocks of variable
length between 2 and 8
Duration: April 1999 to August 2000 for recruitment
Participants Number: 1655 enrolled, 1621 randomised
Inclusion criteria: aged 60 days to 12 months, male or female
Exclusion criteria: known or suspected tuberculosis, chronic respiratory or congenital
heart disease, severe malnutrition requiring hospital admission
Interventions Group 1: zinc acetate 70 mg once weekly for 12 months
Group 2: placebo identical in colour odour and taste once weekly for 12 months
Outcomes Included in the review
Mean number of episodes of suppurative otitis media defined as ’purulent ear discharge’.
Suspected cases were found during once-weekly home visits by trained research assistants
using a standardised calendar questionnaire, then referred to the clinic for a definite
diagnosis
Not included in the review
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Brooks 2005 (Continued)
Episodes of diagnosed diarrhoea, upper respiratory tract infection, reactive airways dis-
ease or bronchiolitis, pneumonia, and severe pneumonia. Cases were found during once-
weekly home visits by trained research assistants using a standardised calendar question-
naire
Death
Height and weight
Serum zinc and copper, blood haemoglobin and white blood cells
Notes Location: Kamalapur, southeastern Dhaka, Bangladesh
Setting: poor, urban community
Source of funding: Johns Hopkins Family Health and Child Survival Cooperative Agree-
ment with the US Agency for International Development, the Swiss Development Cor-
poration, and a co-operative agreement between US Agency for International Develop-
ment and core donors to the Centre for Health and Population Research
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Random assignment...was done
with permuted blocks of variable length be-
tween two and eight”
Comment: probably done
Allocation concealment? Yes Quote: “ACME Laboratories, Ltd pre-
pared, labelled and masked the identity of
both preparations”
Comment: done
Blinding?
All outcomes
Yes Quote: “The placebo was designed to be
identical to the zinc syrup in colour, odour
and taste”
Comment: done
Incomplete outcome data addressed?
Otitis media
Yes Data were included in the analysis up the
point of a child’s withdrawal, even if they
did not complete the observation period.
Exit interviews were done for all drop-outs,
to determine any possible biases
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
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Gardner 2005
Methods Randomised controlled trial. Stratified randomisation in 2 age groups
Duration: not stated
Participants Number: 126 enrolled
Inclusion criteria: age 9 to 30 months (stratified 9 to 18 months and 19 to 30 months),
male or female, weight for age z-score below -1.5 SDs of the National Centre for Health
Statistics references, weight for age below -2 SDs of the National Centre for Health
Statistics references
Exclusion criteria: twins, children with physical or mental impairments that could affect
development
Interventions Group 1: 10 mg elemental zinc as zinc sulphate were given daily, as a flavoured syrup,
for 6 months
Group 2: placebo with identical appearance, odour and taste
The trial had a factorial design, with some children in the zinc and placebo groups also
receiving psychosocial stimulation. All children in both zinc and placebo groups also
received a brand of mixed micronutrients containing vitamins and iron
Outcomes Included in the review
Number of episodes of illness, and number of days ill. Pain or discharge from the ear
recorded by a fieldworker visiting the families every 7th day
Not included in the review
Development using 4 sub-scales of theGriffithsMentalDevelopment Scales at enrolment
and at 6 months
Weight, length, weight-for-age z-score, height-for-age z-score, at enrolment and at 6
months
Number of episodes of illness, and number of days ill. Symptoms recorded by a field-
worker visiting the families every 7th day: apathy, anorexia, fever, coughing, nasal dis-
charge, diarrhoea, vomiting, rapid or difficult breathing, any skin condition. Clinic visits
for illness, and hospital admissions were also recorded
Notes Location: the parishes of Kingston, St Andrew and St Catherine, Jamaica
Setting: nutrition clinics (outpatients)
Source of funding: the Nestle Foundation, The Grace Kennedy Foundation (Jamaica)
. Dr Jeffrey Meeks and the Matalon and Methado families provided further financial
assistance. Zinc supplement donated by Federated Pharmaceuticals Limited
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “...randomly assigned to receive
zinc supplement or placebo”
Comment: probably done, but methods
not described
Allocation concealment? Unclear Not described
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Gardner 2005 (Continued)
Blinding?
All outcomes
Unclear The participants were blinded using place-
bos, but blinding of investigators is not de-
scribed
Incomplete outcome data addressed?
Otitis media
Yes 114 of 126 participants (91%) completed
the study and were included in the analysis.
The trial authors report that the children
whowithdrew were not significantly differ-
ent from those remaining in the study
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
Heinig 2006
Methods Randomised controlled trial (individual randomisation stratified by sex)
Duration: November 1994 to August 1997 for recruitment and data collection
Participants Number: 85 enrolled and randomised
Inclusion criteria: healthy male or female term infant weighing > 2500 g, healthy non-
smoking mother, mother planning to breast feed (without using formula milk on a daily
basis) for ≥ 10 months, and not to introduce complementary food before 4 months.
Infants were recruited within 3 months of birth, and included in the trial between the
ages of 4 and 10 months
Exclusion criteria: mother under 19 years old, chronic medical condition that may
interfere with lactation, planning to leave the study area during the study period
Interventions Group 1: 5 mg elemental zinc (as zinc sulphate) in drops each day between the ages 4
and 10 months
Group 2: placebo drops
Outcomes Included in the review
Episodes of physician diagnosed otitis media per 100 child days at risk
Not included in the review
Length,weight, head circumference,midarmcircumference, skinfold thickness at triceps,
subscapular, flank and quadriceps at ages 4 and 10 months
Plasma zinc, iron, copper, ferritin, immunoglobulin G2 and G4; and erythrocyte super-
oxide dismutase at ages 4 and 10 months
Timing of introduction of complementary foods, nutrient intake from complementary
foods
Respiratory illness, diarrhoea, fever (without other symptoms), other illness
Motor development measured using Alberta Infant Motor Scale
Notes Location: USA
Setting: community setting, recruitment through local paediatrician’s offices
Source of funding: US Department of Agriculture
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Heinig 2006 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomassignment to groupswas
done by using the Moses-Oakford algo-
rithm”
Comment: done
Allocation concealment? Yes Quote: “An assistant who was not in con-
tactwith the study subjects labelled the bot-
tles with 1 of 4 colours”
Comment: done
Blinding?
All outcomes
Yes Quote: “Each mother-infant pair was as-
signed to a colour group so that neither
the primary investigator nor the mothers
would know whether the infants received
the zinc supplement”
Comment: done
Incomplete outcome data addressed?
Otitis media
Yes 70 of 85 participants (82%) were included
in the analysis. Of these, 3 were lost to fol-
low up and 12 became ineligible because of
consumption of formula milk. The analy-
sis was undertaken both including and ex-
cluding the 12 ineligible participants and
the findings were the same; therefore data
are presented only for the 70 infants who
completed the trial
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Unclear Not clear how participants were originally
selected
Lind 2004
Methods Randomised controlled trial
Duration: July 1997 to May 1999
Participants Number: 680 randomised
Inclusion criteria: healthy male or female singleton infants under 6 months of age
Exclusion criteria: metabolic or neurological disorders; handicaps affecting development,
feeding or activity; severe or protracted illness; haemoglobin < 90 g/L
22Zinc supplements for preventing otitis media (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lind 2004 (Continued)
Interventions Group 1: 10 mg iron as ferrous sulphate
Group 2: 10 mg zinc as zinc sulphate
Group 3: 10 mg iron plus 10 mg zinc
Group 4: placebo
All interventions given as a sweet-tasting syrup, given daily for 6 months
Outcomes Included in the review
Total number of days (for entire trial treatment groups) with ear discharge recorded by
a fieldworker visiting families every 3rd day
Not included in the review
Weight, length, and knee-heel length, head circumference and mid arm circumference
at 12 months of age
Infant development, measured using the Bayley Scales of Infant Development, at 12
months of age
Symptoms recorded by a fieldworker visiting the families every third day: fever (moth-
ers own definition), coryza, cough, difficult or rapid breathing, diarrhoea or vomiting.
Incidence of diarrhoeal disease and lower respiratory infections during the 6 months of
the trial were the primary outcomes
Perceived side effects of the intervention
Notes Location: Purworejo, Central Java, Indonesia
Setting: community setting, in a health and demographic surveillance area. Authors
reported a high prevalence of child stunting and micronutrient deficiencies
Source of funding: the Swedish Agency for Research Cooperation with Developing
Countries, the Swedish Medical Research Council, the Swedish Foundation for Interna-
tional Cooperation in Research and Education, the Swedish Medical Society, the Maud
and Birger Gustavsson Foundation, and Umea University Foundation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomization was planned and
generated by an independent statistician
and performed in blocks of 20”
Comment: done
Allocation concealment? Yes Quote: “Randomization was planned and
generated by an independent statisti-
cian”.... “The pharmaceutical company
marked the 4 different supplements with
letter codes to which the researchers and
participants were blinded”
Comment: done
Blinding?
All outcomes
Yes Quote: “Researchers and field staff were
blinded to the information on group as-
signment, because this information was
kept in safes at the administrative offices..
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Lind 2004 (Continued)
until after the intention-to-treat analyses”
Comment: done
Incomplete outcome data addressed?
Otitis media
Yes 662 of 680 participants (97%) had com-
plete morbidity data. Analysis showed no
differences between those who completed
the trial and those who did not
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
Muller 2001
Methods Randomised controlled trial (randomisation in blocks of 30)
Duration: June 1999 to December 1999
Participants Number: 709 enrolled and randomised
Inclusion criteria: aged between 6 and 31 months, male or female, permanent residents
in participating villages
Exclusion criteria: serious underlying disease, absence for more than 14 consecutive days
during the study period
Interventions Group 1: 12.5 mg zinc sulphate, in tablet form, daily (except Sundays) for 6 months
Group 2: placebo identical in appearance and taste
Outcomes Included in the review
Number of children with at least 1 episode of clinically diagnosed otitis media, at period
cross-sectional surveys
Not included in the review
Daily reports, for 6 months, from the parents on reported symptoms other than earache,
visits to healthcare providers, and any treatments received
Incidence of malaria, detected by daily temperature monitoring and testing of children
with a temperature of 37.5 C or higher
At baseline, 3 months and 6 months, cross-sectional survey data including: personal
characteristics and risk factors (age, sex, ethnicity, use of mosquito nets), clinical data
(including diagnosed otitis media), anthropometric data (weight, height or length, mid
arm circumference) and malaria parasite density from thick and thin blood films. Packed
cell volumes and serum zinc concentrations were measured in a random sample of 100
Notes Location: 18 villages in rural northwestern Burkina Faso
Setting: community setting, in rural area where malaria is common
Source of funding: the World Health Organization and Deutsche Forschungsgemein-
schaft
Risk of bias
Item Authors’ judgement Description
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Muller 2001 (Continued)
Adequate sequence generation? Yes Quote: “Children were allocated zinc or
placebo in blocks of 30 by computer gen-
erated random permutated codes”
Comment: done
Allocation concealment? Yes Quote: “Children were allocated by com-
puter generated random permuted codes
(prepared by the World Health Organiza-
tion)”
Comment: done
Blinding?
All outcomes
Yes Quote: “The tablets were identical in ap-
pearance and taste”
“The randomization code was broken after
the database was closed”
Comment: done
Incomplete outcome data addressed?
Otitis media
Yes 685 of 709 (97%) children were included
in the analysis. Children absent from the
trial formore than14 consecutive dayswere
excluded
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes Participants selected for the study ran-
domly
Penny 2004
Methods Randomised controlled trial. Block randomisation, stratified by current breastfeeding
status
Duration: not stated
Participants Number: 246 enrolled
Inclusion criteria: aged 6 to 36 months with diarrhoea for ≥14 days, male or female,
intending to remain in the study area the next 6 months
Exclusion criteria: none stated
Interventions Group 1: 20 mg zinc per day as zinc gluconate
Group 2: 20 mg zinc per day as zinc gluconate plus a mixture of other micronutrients
Group 3: placebo
The 3 interventions were indistinguishable by taste and appearance. They were in the
form of a dry powder with added sugar, flavouring and colouring, and were administered
by dissolving in boiled water in the participants’ homes
All interventions were given daily for 6 months after the episode of diarrhoea had ended
Outcomes Included in the review
Incidence and prevalence of ear infection, assessed by field workers who made daily visits
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Penny 2004 (Continued)
to the children’s home, asked the caregivers about symptoms and examined the child if
new symptoms or worsening of existing symptoms was reported. (Awaiting data from
author)
Not included in the review
Incidence and prevalence of various illnesses and symptoms, assessed by field workers
who made daily visits to the children’s home, asked the caregivers about symptoms and
examined the child if new symptoms or worsening of existing symptoms were reported.
Illnesses reported on included diarrhoea, cough, lower respiratory infection, pneumonia,
fever, anorexia
Weight, length, mid-upper arm circumference, and skinfold thicknesses on biceps, tri-
ceps, suprailiac, subscapular. Measured at baseline, 15 days, then monthly
Haemoglobin, haematocrit and plasma zinc measured at baseline, 15 days, and 6months
Notes Location: Canto Grande, a shanty town on the outskirts of Lima, Peru
Setting: community setting
Source of funding: Thrasher Research Fund and the World Health Organization; addi-
tional funds were provided by the University of California Pacific Rim Programme
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “With the use of a computer-gen-
erated, block randomization scheme...”
Comment: done
Allocation concealment? Yes Quote: “Each study number had been
linked previously to 1 of 9 letter codes, each
of which indicated one of the three treat-
ment groups”
Comment: done
Blinding?
All outcomes
Yes Quote: “The identities of the codes were
not available to the field staff or investiga-
tors until after the data had been cleaned
and analysed”
Comment: done
Incomplete outcome data addressed?
Otitis media
Yes 6/246 (2%) children were withdrawn from
the study by their parents. For the remain-
ing children, informationonmorbiditywas
available for > 90% of days during the pe-
riod of supplementation
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
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Prasad 1999
Methods Randomised controlled trial
Duration: 4 years
Participants Number: 21 enrolled
Inclusion criteria: adults (male or female) with sickle cell disease, sickle cell haemoglobin
C, or sickle cell beta thalassaemia, who were attending a clinic, and who were identified
as zinc-deficient using cellular zinc levels and immunological parameters
Exclusion criteria: non-ambulatory, receiving more than 6 transfusions per year, drug
dependent, neurological or psychiatric deficits, taking immunosuppressive drugs, HIV
positive, hepatitis B, already taking zinc supplements
Interventions Group 1: no supplement for 1 year, placebo for 1 year, followed by 50 mg elemental zinc
as zinc acetate daily for 2 years
Group 2: 50 mg elemental zinc as zinc acetate daily for 3 years
Outcomes Infections, classified by type and diagnosed at the clinic
Notes Location: Detroit, USA
Source of funding: FDA grant
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Mentioned “randomized groups”
Allocation concealment? Unclear Not stated
Blinding?
All outcomes
Yes “Acutely symptomatic, febrile patients
were evaluated by an infectious disease con-
sultant who was a blinded observer”
Incomplete outcome data addressed?
Otitis media
Yes No loss to follow up
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
Prasad 2007
Methods Randomised controlled trial
Duration: 12 months
Participants Number: 50 enrolled
Inclusion criteria: elderly men and women attending a senior citizens’ centre
Exclusion criteria: life expectancy less than 8 months, progressive neoplastic disease,
significant kidney disease, significant liver disease, people self-supplementing with zinc,
people unable to provide informed consent for participation
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Prasad 2007 (Continued)
Interventions Group 1: one capsule zinc gluconate (15 mg elemental zinc) every day for 12 months
Group 2: placebo capsules every day in the same manner
Outcomes Any infection, classified by type of infection, diagnosed by a nurse practitioner
Notes Location: Detroit, USA
Source of funding: NIH grant and Labcatal Laboratories, France
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Elderly subjects were randomly as-
signed in pairs to the zinc supplemented or
the placebo group with the use of envelopes
that each contained two smaller envelopes”
Comment: done
Allocation concealment? Yes Quote: “Elderly subjects were randomly as-
signed in pairs to the zinc supplemented or
the placebo group with the use of envelopes
that each contained two smaller envelopes”
Comment: done
Blinding?
All outcomes
Yes Quote: “The nurse practitioner was
blinded to the treatment assignment”
Quote: “The persons caring for the pa-
tient...were blinded to the assignment”
Incomplete outcome data addressed?
Otitis media
Unclear One participants dropped out of the study
on day 2. There was no other loss to follow
up
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of any other bias
Schlesinger 1992
Methods Randomised controlled trial
Duration: not stated
Participants Number: 39 enrolled
Inclusion criteria: marasmic infants, male or female
Exclusion criteria: none stated
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Schlesinger 1992 (Continued)
Interventions Group 1: zinc fortified (zinc chloride 15 mg/L) nutritional recovery formula, based on
full fat powdered cow milk
Group 2: identical nutritional recovery formula, but without the zinc
Interventions were given daily for 105 days
Outcomes Included in the review
Mean number of episodes of ear suppuration, detected by daily recording of signs and
symptoms
Not included in the review
Haemoglobin, ferritin, plasma zinc and copper, anaemia and iron stores at admission,
30 days, 60 days and 105 days
Height for age, weight for age and height for weight z-scores at admission, 30 days, 60
days and 105 days
Positive skin tests indicating immunocompetence at admission and 105 days
Mean number of episodes, mean duration of days of each episode and mean percentage
of infected days with illness for upper respiratory infection, lower respiratory infection,
acute diarrhoea, skin and mucous candidiasis, purulent conjunctivitis, within the 105
days duration. These were detected by daily recording of signs and symptoms
Notes Location: Santiago, Chile
Setting: nutritional recovery centre inpatients
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described
Allocation concealment? Unclear No described
Blinding?
All outcomes
Unclear Quote: “controlled double blind design”
Comment: probably done, but methods
not described
Incomplete outcome data addressed?
Otitis media
Yes 39 of 39 participants (100%) included in
the analysis
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Unclear Not enough information provided about
the methods
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Wuehler 2008
Methods Randomised controlled trial
Duration: November 2001 to April 2005
Participants Number: 631 enrolled
Inclusion criteria: children 12 to 29 months old, male or female, length for age z-score <
-1.3 for children 12 to 20 months old, < -1.5 for children 21 to 29 months old (stunted)
, assessed by comparison with WHO/NCHS international reference data. All received
iron supplements for 1 month before the start of the trial
Exclusion criteria: anaemia assessed by haemoglobin < 10.5 g/dL, adjusted for altitude,
chronic disease or congenital defect that restricts normal growth
Interventions Group 1: placebo
Group 2: 3 mg zinc per day
Group 3: 7 mg zinc per day
Group 4: 10 mg zinc per day
Group 5: 10 mg zinc plus 0.5 mg copper per day
Zinc was given as zinc sulphate and copper given as copper sulphate. All supplements
were given for 6 months
Outcomes Included in the review
Earache or discharge from the ear during each day, recorded during home visits 3 to 5
times per week using a systematic, symptom-based questionnaire and observation of the
child
Not included in the review
Child’s general health status, appetite, number and consistency of stools, symptoms of
cough, fever, nasal discharge, vomiting
Length and weight at 0, 3 and 6 months
Zinc, iron and copper status as measured in blood samples
Notes Location: Ecuador, various communities
Source of funding: US Department of Agriculture, US Agency for International Devel-
opment Micronutrient Program, the United Nations Children Fund, Bristol-Meyers/
Squibb Freedom to Discover grant, and Grupo Farma del Ecuador
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “The randomization lists..were
generated..by using a fixed block random-
ization procedure”
Decision: done
Allocation concealment? Unclear Not described
Blinding?
All outcomes
Unclear Quote: “double -masked”
Decision: unclear, probably done
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Wuehler 2008 (Continued)
Incomplete outcome data addressed?
Otitis media
Yes 30 days or more of morbidly data was ob-
tained for 590 of 631 participants (94%)
Free of selective reporting? Yes No evidence of selective reporting
Free of other bias? Yes No evidence of other bias
Characteristics of excluded studies [ordered by study ID]
Abdulhamid 2008 No relevant outcomes
Al-Sonboli 2003 No relevant outcomes
Arsenault 2008 No relevant outcomes
Bacqui 2002 No relevant outcomes
Bacqui 2003 No relevant outcomes
Bates 1993 No relevant outcomes
Behrens 1990 No relevant outcomes
Bhandari 2007 No relevant outcomes
Bhutta 1999 No relevant outcomes
Bogden 1988 No relevant outcomes
Bogden 1990 No relevant outcomes
Boran 2006 No relevant outcomes
Brooks 2004 No relevant outcomes
Brooks 2005a No relevant outcomes
Brown 2007 No relevant outcomes
Carcamo 2006 No relevant outcomes
Castillo-Duran 1987 No relevant outcomes
Castillo-Duran 1995 No relevant outcomes
Castillo-Duran 2001 No relevant outcomes
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Cavan 1993 No relevant outcomes
Chang 2006 No relevant outcomes
Coles 2008 No relevant outcomes
Czerwinski 1974 No relevant outcomes
Dehbozorgi 2007 No relevant outcomes
Dijkhuizen 2001 No relevant outcomes
Dijkhuizen 2008 No relevant outcomes
Doherty 1998 No relevant outcomes
Duchateau 1981 Not a randomised controlled trial
Dutta 2000 No relevant outcomes
Eggert 1982 No relevant outcomes
Ertekin 2003 No relevant outcomes
Fahmida 2007 No relevant outcomes
Fajolu 2008 No relevant outcomes
Faruque 1999 No relevant outcomes
Fawzi 2005 No relevant outcomes
Fischer Walker 2007 No relevant outcomes (contacted trial author for clarification)
Fischer Walker 2009 No relevant outcomes
Floersheim 1980 Not a randomised controlled trial
Fortes 1998 No relevant outcomes
Friel 1993 No relevant outcomes
Friis 1997 No relevant outcomes
Giroden 1999 Intervention is not zinc alone (zinc plus selenium sulphide)
Golden 1978 Intervention is not oral zinc (topical zinc cream)
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(Continued)
Goransson 1978 No relevant outcomes
Grazioso 1993 No relevant outcomes
Gupta 1995 No relevant outcomes
Gupta 2003 No relevant outcomes
Hambridge 1993 No relevant outcomes
Hemalatha 1993 No relevant outcomes
Hettiarachchi 2008 No relevant outcomes
Hodkinson 2007 No relevant outcomes
Intorre 2008 No relevant outcomes
Johnson 2007 No relevant outcomes
Jonsson 1996 No relevant outcomes
Khanum 1988 No relevant outcomes
Khatun 2001 No relevant outcomes
Kilic 1998 No relevant outcomes
Kurogol 2007 No relevant outcomes
Labadie 1986 No relevant outcomes
Lin 2008 No relevant outcomes
Linday 2004 Not a randomised controlled trial
Lira 1998 No relevant outcomes
Lockitch 1989 No relevant outcomes
Long 2006 No relevant outcomes
Mahomed 1989 No relevant outcomes
Makonnen 2003 No relevant outcomes
Mocchegiani 1995 No relevant outcomes
Mocchegiani 1999 Not a randomised controlled trial
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Muller 2003 No relevant outcomes
Munguia 2003 No relevant outcomes
Naheed 2009 Zinc supplements given for less than 1 month
Osendarp 2002 No relevant outcomes
Osendarp 2007 No relevant outcomes
Oyoke 2008 Review article
Rahman 2002 No relevant outcomes
Rawer 1987 No relevant outcomes
Rivera 1998 No relevant outcomes
Rosado 1997 No relevant outcomes
Roy 1997 No relevant outcomes
Roy 1999 Supplements given for a shorter period than 1 month
Roy 2007 Intervention not zinc alone (zinc plus multivitamins)
Roy 2008 Supplements given for a period shorter than 1 month
Roy 2008b No relevant outcomes
Ruel 1997 No relevant outcomes (checked with author)
Ruz 1997 No relevant outcomes
Sachdev 1990 No relevant outcomes
Safai-Kutti 1990 Not a randomised controlled trial
Safai-Kutti 1991 No relevant outcomes
Samman 1987 No relevant outcomes
Sancho Martinez 2007 Not a randomised controlled trial (review article)
Sazawal 1995 No relevant outcomes
Sazawal 1996 No relevant outcomes
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Sazawal 2001 No relevant outcomes
Sazawal 2007 No relevant outcomes
Shankar 2000 No relevant outcomes
Silva 2006 No relevant outcomes
Simmer 1988 Not a randomised controlled trial
Simmer 1991 No relevant outcomes
Singh 1994 No relevant outcomes
Smith 1999 No relevant outcomes
Sur 2003 No relevant outcomes
Thu 1999 Intervention not zinc alone (multiple micronutrients)
Tielsch 2007 No relevant outcomes
Udomkesmalee 1992 No relevant outcomes
Valery 2005 No relevant outcomes
Van Horn 2003 Intervention not zinc (promotion of diet low in saturated fat)
Vasudevan 1997 No relevant outcomes
Walravens 1976 No relevant outcomes
Walravens 1989 No relevant outcomes
Walravens 1992 No relevant outcomes
Wasantwisut 2006 No relevant outcomes
Wazewska-Czyzewska 1978 No relevant outcomes
Weismann 1978 No relevant outcomes
Weismann 1979 No relevant outcomes
Wieringa 2007 No relevant outcomes
Yang 2002 No relevant outcomes
Zeba 2008 Intervention not zinc alone (zinc plus vitamin A)
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Zemel 2002 No relevant outcomes
Characteristics of studies awaiting assessment [ordered by study ID]
Berger 2006
Methods Randomised controlled trial
Duration: March to November 1998
Participants Number: 933 enrolled
Inclusion criteria: singleton breast fed infants, between 4 and 7 months of age
Exclusion criteria: chronic or acute illness, severe malnutrition or congenital abnormality
Interventions Group 1: 10 mg iron daily as ferrous sulphate
Group 2: 10 mg zinc daily as zinc sulphate
Group 3: 10 mg zinc daily as zinc sulphate plus 10 mg iron as ferrous sulphate
Group 4: placebos
Supplements were given 7 days per week for 6 months by trained field workers
Outcomes Serum haemoglobin, ferritin, and zinc; anaemia; height and weight; number of episodes of and number of days with
acute respiratory infection, cough, fever, and diarrhoea
Notes Location: rural area of Vietnam
Source of funding: UNICEF, New York
Ninh 1996
Methods Randomised controlled trial
Duration: 5 months (dates not stated)
Participants Number: 210 enrolled
Inclusion criteria: children aged 4 to 36 months with growth retardation evidenced byWAZ score below -2 and HAZ
score below -2, and no obvious medical reasons for poor growth
Exclusion criteria: none stated
Interventions Group 1: 10 mg zinc as zinc sulphate
Group 2: placebo
Doses of zinc and placebo were given daily for 5 months
Outcomes Height and weight, respiratory infections, diarrhoea
Notes Location: rural area of Vietnam
Source of funding: University of Louvain and the National Institute of Nutrition of Vietnam
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Richard 2006
Methods Randomised controlled trial
Duration: February to September 1998
Participants Number: 855 enrolled
Inclusion criteria: children aged 6 months to 15 years of age
Exclusion criteria: chronic illness or severe malnutrition
Interventions Group 1: 15 mg iron as iron sulphate
Group 2: 15 mg zinc as zinc sulphate
Group 3: 15 mg iron as iron sulphate plus 15 mg zinc as zinc sulphate
Group 4: placebos
All supplements were given daily for 7 months
Outcomes Height and weight; haemoglobin status; zinc status; diarrhoea, fever, vomiting, coughing, and a variety of other
symptoms. Diagnoses of malaria, diarrhoea, and acute lower respiratory infection
Notes Location: rural village in Peru
Source of funding: United Nations Children’s Fund and United States Agency for International Development
HAZ: height-for-age z-score
WAZ: weight-for-age z-score
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D A T A A N D A N A L Y S E S
Comparison 1. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Individuals who had at least one
episode of definite otitis media
of any duration
2 3191 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.82, 1.36]
2 Individuals who had more than
one episode of definite otitis
media
1 2482 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.50, 2.36]
3 Mean number of episodes of
definite otitis media
1 39 Mean Difference (IV, Fixed, 95% CI) -1.12 [-2.21, -0.03]
4 Rate ratio episodes of definite
otitis media
1 Rate Ratio (Fixed, 95% CI) 0.69 [0.61, 0.79]
5 Individuals who had at least one
case of probable otitis media
1 2482 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.80, 1.22]
6 Mean days with probable otitis
media
1 3145 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.45, 0.65]
7 Total number of days with ear
discharge
1 60698 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.33, 0.97]
8 Days with vomiting after
supplementation
1 2482 Mean Difference (IV, Fixed, 95% CI) 1.70 [1.31, 2.09]
9 At least one episode of
vomiting immediately after
supplementation
1 326 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.93, 1.79]
10 Discontinued supplement due
to vomiting
1 2482 Risk Ratio (M-H, Fixed, 95% CI) 17.0 [0.98, 294.21]
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Analysis 1.1. Comparison 1 Zinc versus placebo, Outcome 1 Individuals who had at least one episode of
definite otitis media of any duration.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 1 Individuals who had at least one episode of definite otitis media of any duration
Study or subgroup Zinc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bhandari 2002 99/1241 99/1241 90.8 % 1.00 [ 0.77, 1.31 ]
Muller 2001 16/356 10/353 9.2 % 1.59 [ 0.73, 3.45 ]
Total (95% CI) 1597 1594 100.0 % 1.05 [ 0.82, 1.36 ]
Total events: 115 (Zinc), 109 (Placebo)
Heterogeneity: Chi2 = 1.21, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 0.41 (P = 0.68)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.2. Comparison 1 Zinc versus placebo, Outcome 2 Individuals who had more than one episode of
definite otitis media.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 2 Individuals who had more than one episode of definite otitis media
Study or subgroup Zinc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bhandari 2002 13/1241 12/1241 100.0 % 1.08 [ 0.50, 2.36 ]
Total (95% CI) 1241 1241 100.0 % 1.08 [ 0.50, 2.36 ]
Total events: 13 (Zinc), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.3. Comparison 1 Zinc versus placebo, Outcome 3 Mean number of episodes of definite otitis
media.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 3 Mean number of episodes of definite otitis media
Study or subgroup Zinc Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schlesinger 1992 19 0.73 (0.9) 20 1.85 (2.3) 100.0 % -1.12 [ -2.21, -0.03 ]
Total (95% CI) 19 20 100.0 % -1.12 [ -2.21, -0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
-100 -50 0 50 100
Favours experimental Favours control
Analysis 1.4. Comparison 1 Zinc versus placebo, Outcome 4 Rate ratio episodes of definite otitis media.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 4 Rate ratio episodes of definite otitis media
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brooks 2005 -0.369 (0.065) 100.0 % 0.69 [ 0.61, 0.79 ]
Total (95% CI) 100.0 % 0.69 [ 0.61, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.68 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.5. Comparison 1 Zinc versus placebo, Outcome 5 Individuals who had at least one case of
probable otitis media.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 5 Individuals who had at least one case of probable otitis media
Study or subgroup Zinc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bhandari 2002 149/1241 151/1241 100.0 % 0.99 [ 0.80, 1.22 ]
Total (95% CI) 1241 1241 100.0 % 0.99 [ 0.80, 1.22 ]
Total events: 149 (Zinc), 151 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.6. Comparison 1 Zinc versus placebo, Outcome 6 Mean days with probable otitis media.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 6 Mean days with probable otitis media
Study or subgroup Zinc Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bhandari 2002 1241 1.6 (7.9) 1904 1.5 (7.4) 100.0 % 0.10 [ -0.45, 0.65 ]
Total (95% CI) 1241 1904 100.0 % 0.10 [ -0.45, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
-100 -50 0 50 100
Favours experimental Favours control
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Analysis 1.7. Comparison 1 Zinc versus placebo, Outcome 7 Total number of days with ear discharge.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 7 Total number of days with ear discharge
Study or subgroup Zinc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lind 2004 21/30275 37/30423 100.0 % 0.57 [ 0.33, 0.97 ]
Total (95% CI) 30275 30423 100.0 % 0.57 [ 0.33, 0.97 ]
Total events: 21 (Zinc), 37 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.040)
0.01 0.1 1 10 100
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Analysis 1.8. Comparison 1 Zinc versus placebo, Outcome 8 Days with vomiting after supplementation.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 8 Days with vomiting after supplementation
Study or subgroup Zinc Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bhandari 2002 1241 4.3 (5.8) 1241 2.6 (3.9) 100.0 % 1.70 [ 1.31, 2.09 ]
Total (95% CI) 1241 1241 100.0 % 1.70 [ 1.31, 2.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.57 (P < 0.00001)
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Analysis 1.9. Comparison 1 Zinc versus placebo, Outcome 9 At least one episode of vomiting immediately
after supplementation.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 9 At least one episode of vomiting immediately after supplementation
Study or subgroup Zinc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lind 2004 56/162 44/164 100.0 % 1.29 [ 0.93, 1.79 ]
Total (95% CI) 162 164 100.0 % 1.29 [ 0.93, 1.79 ]
Total events: 56 (Zinc), 44 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 1.10. Comparison 1 Zinc versus placebo, Outcome 10 Discontinued supplement due to vomiting.
Review: Zinc supplements for preventing otitis media
Comparison: 1 Zinc versus placebo
Outcome: 10 Discontinued supplement due to vomiting
Study or subgroup Zinc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bhandari 2002 8/1241 0/1241 100.0 % 17.00 [ 0.98, 294.21 ]
Total (95% CI) 1241 1241 100.0 % 17.00 [ 0.98, 294.21 ]
Total events: 8 (Zinc), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
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A P P E N D I C E S
Appendix 1. EMBASE search strategy
1. ’zinc’/exp
2. zinc:ti,ab
3. ’diet supplementation’/exp
4. #1 OR #2 OR #3
5. ’randomized controlled trial’/exp
6. ’single blind procedure’/exp
7. ’double blind procedure’/exp
8. ’crossover procedure’/exp
9. (random*:ti,ab OR factorial*:ti,ab OR crossover*:ti,ab OR placebo*:ti,ab OR assign*:ti,ab OR allocat*:ti,ab OR volunteer*:ti,ab)
OR ’cross over’:ti,ab OR ’single blind’:ti,ab OR ’single blinded’:ti,ab
OR ’single blinding’:ti,ab OR ’double blind’:ti,ab OR ’double blinding’:ti,ab OR ’double blinded’:ti,ab
10. #5 OR #6 OR #7 OR #8 OR #9
11. #4 AND #10
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